日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib

综合群体药代动力学、药效学和安全性分析,为ATR抑制剂Tuvusertib的临床开发中的剂量选择提供信息

Mukker, Jatinder Kaur; Diderichsen, Paul Matthias; Hellmann, Farina; Yap, Timothy A; Plummer, Ruth; Tolcher, Anthony W; de Bono, Johann S; Gounaris, Ioannis; Szucs, Zoltan; Zimmermann, Astrid; Kareva, Irina; Bolleddula, Jayaprakasam; Seithel-Keuth, Annick; Locatelli, Giuseppe; Enderlin, Marta; Hicking, Christine; Zutshi, Anup; Gao, Wei; Strotmann, Rainer; Benincosa, Lisa; Venkatakrishnan, Karthik

Establishing Immune Correlates of Protection Against Respiratory Syncytial Virus Infection to Accelerate Vaccine Development: A Model-Based Meta-Analysis

建立呼吸道合胞病毒感染保护性免疫相关性以加速疫苗研发:基于模型的荟萃分析

Kashihara, Yushi; Qin, Li; Shimizu, Shinji; Diderichsen, Paul Matthias; Kotsuma, Masakatsu; Yoshihara, Kazutaka

An Integrated Nonclinical and Clinical Risk Assessment of the Effects of Investigational ATRi Tuvusertib on QTc Interval in Patients With Solid Tumors

研究性ATRi药物Tuvusertib对实体瘤患者QTc间期影响的非临床和临床综合风险评估

Mukker, Jatinder Kaur; Yap, Timothy A; Tolcher, Anthony W; de Bono, Johann S; Plummer, Ruth; Grosser, Gary; van Amsterdam, Christoph; Schieferstein, Hanno; Witjes, Han; Diderichsen, Paul Matthias; Krebs-Brown, Axel; Gao, Wei; Strotmann, Rainer; Szucs, Zoltan; Gounaris, Ioannis; Venkatakrishnan, Karthik

Exposure-Response Analyses of Sacituzumab Govitecan Efficacy and Safety in Patients With Metastatic Triple-Negative Breast Cancer

Sacituzumab Govitecan治疗转移性三阴性乳腺癌患者的疗效和安全性暴露-反应分析

Sathe, Abhishek G; Diderichsen, Paul M; Fauchet, Floris; Phan, See-Chun; Girish, Sandhya; Othman, Ahmed A

Population Pharmacokinetic and Exposure-Response Analyses for Ponatinib in the Phase 3 PhALLCON Study

Ponatinib 在 3 期 PhALLCON 研究中的群体药代动力学和暴露-反应分析

Hanley, Michael J; Larson, Thomas R; Diderichsen, Paul M; Largajolli, Anna; Hui, Katrina; Srimani, Jaydeep; Wang, Bingxia; Vorog, Alexander; Gupta, Neeraj

Sacituzumab Govitecan Population Pharmacokinetics: Updated Analyses Using HR+/HER2- Metastatic Breast Cancer Data From the Phase 3 TROPiCS-02 Trial

Sacituzumab Govitecan 群体药代动力学:基于 TROPiCS-02 3 期试验中 HR+/HER2- 转移性乳腺癌数据的最新分析

Sathe, Abhishek G; Jones, Aksana K; Diderichsen, Paul M; Wang, Xiaohui; Chang, Peter; Verret, Wendy; Girish, Sandhya

Disproportionate infection, hospitalisation and death from COVID-19 in ethnic minority groups and Indigenous Peoples: an application of the Priority Public Health Conditions analytical framework

少数族裔和原住民群体中新冠肺炎感染、住院和死亡比例失衡:优先公共卫生状况分析框架的应用

Irizar, Patricia; Pan, Daniel; Taylor, Harry; Martin, Christopher A; Katikireddi, Srinivasa Vittal; Kannangarage, Niluka Wijekoon; Gomez, Susana; La Parra Casado, Daniel; Srinivas, Prashanth Nuggehalli; Diderichsen, Finn; Baggaley, Rebecca F; Nellums, Laura B; Koller, Theadora Swift; Pareek, Manish

Population Pharmacokinetics of Sacituzumab Govitecan in Patients with Metastatic Triple-Negative Breast Cancer and Other Solid Tumors

Sacituzumab Govitecan 在转移性三阴性乳腺癌和其他实体瘤患者中的群体药代动力学

Sathe, Abhishek G; Singh, Indrajeet; Singh, Pratap; Diderichsen, Paul M; Wang, Xiaohui; Chang, Peter; Taqui, Atiya; Phan, See; Girish, Sandhya; Othman, Ahmed A

Prediction of Disease Progression and Clinical Response in Systemic Sclerosis: Experience From a Proof-of-Concept Trial

系统性硬化症疾病进展和临床反应的预测:概念验证试验的经验

Neve, Marta; Diderichsen, Paul M; Helmer, Eric; de Vries, Dick; Taneja, Amit

Agribusiness and the COVID-19 syndemic: The unsustainable pathways

农业综合企业与新冠肺炎疫情:不可持续的道路

Diderichsen, Finn; Friedrich, Karen; Da Silva Giraldo, Lia Augusto